484PRetrospective RAS analysis of the EPIC trial: Cetuximab plus irinotecan vs irinotecan in patients (pts) with second-line metastatic colorectal cancer (mCRC)
2018
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
1
Citations
NaN
KQI